HALBERT JON 4

What Happened
Jon Halbert, a director of Caris Life Sciences (CAI), was granted 2,492 shares on February 26, 2026. The shares were issued at $20.06 each, with a total value of $49,990, as consideration in lieu of cash for 2025 board retainer fees (transaction code A — award/grant). This was an award of shares, not an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-26; Price: $20.06 per share; Shares: 2,492; Total value: $49,990.
• Shares issued in lieu of cash compensation for 2025 board retainer fees; number determined using the 10-trading-day VWAP through Feb 25, 2026 (Footnote F1).
• Reporting person disclaims beneficial ownership except to the extent of his pecuniary interest (Footnote F2).
• Footnote F3 notes a prior in-kind distribution of 1,250,000 shares formerly held by Ke'Ohana Ventures, LLC — 625,000 to the Jon and Linda Halbert Management Trust and 625,000 to LAH Investments, Ltd.
• Filing date: 2026-02-27 (filed the day after the reported transaction) — appears timely under Form 4 reporting rules.

Context
This was a fee award (shares issued in lieu of cash) rather than a market purchase or sale, so it reflects compensation mechanics rather than a direct trading signal of the director’s view on the stock. The disclaimer of beneficial ownership and the prior distribution of shares indicate holdings may be indirect or managed via trusts.